Novel therapy for anti-glomerular basement membrane disease with IgA nephropathy: A case report

Xu,Dechao; Wu,Jianxiang; Wu,Jun; Xu,Chenggang; Zhang,Yuqiang; Mei,Changlin; Gao,Xiang

doi:10.3892/etm.2016.3149

Novel therapy for anti-glomerular basement membrane disease with IgA nephropathy: A case report

Authors:
- Dechao Xu
- Jianxiang Wu
- Jun Wu
- Chenggang Xu
- Yuqiang Zhang
- Changlin Mei
- Xiang Gao
View Affiliations

Affiliations: Department of Medicine, Kidney Institute of PLA, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China, Department of Geriatrics, No. 411 Hospital of PLA, Shanghai 200081, P.R. China
Published online on: March 11, 2016 https://doi.org/10.3892/etm.2016.3149
Pages: 1889-1892

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anti-glomerular basement membrane (GBM) disease is characterized by circulating anti-GBM antibodies and deposition of these antibodies in the renal GBM. Renal involvement in anti‑GBM is more severe when compared with other types of immune-mediated glomerulonephritis, and the majority of patients manifest progressive renal failure, leading to end‑stage renal disease. In a limited number of cases, anti‑GBM disease has been shown to be accompanied with other immune‑mediated glomerulonephritis. The present study reported the case of a 50‑year‑old female patient presenting with rapidly progressive glomerulonephritis, who was diagnosed with anti‑GBM disease with IgA nephropathy. The patient achieved a relatively good therapeutic outcome with administration of corticosteroids plus mycophenolate mofetil (MMF), which may prove to be a novel treatment option for this rare disease; however, the exact underlying mechanism requires further in‑depth investigation.

View Figures

View References

1	Lahmer T and Heemann U: Anti-glomerular basement membrane antibody disease: a rare autoimmune disorder affecting the kidney and the lung. Autoimmun Rev. 12:169–173. 2012. View Article : Google Scholar : PubMed/NCBI
2	Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, et al: Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med. 363:343–354. 2010. View Article : Google Scholar : PubMed/NCBI
3	Tang W, McDonald SP, Hawley CM, Badve SV, Boudville NC, Brown FG, Clayton PA, Campbell SB, de Zoysa JR and Johnson DW: Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int. 83:503–510. 2013. View Article : Google Scholar : PubMed/NCBI
4	Cui Z and Zhao MH: Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol. 7:697–705. 2011. View Article : Google Scholar : PubMed/NCBI
5	Jennette JC and Nickeleit V: Anti-glomerular basement membrane glomerulonephritis and Goodpasture's syndrome. Heptinstall's Pathology of the Kidney. Jennette JC, Olson JL, Schwartz MM and Silva FG: (6th). Lippincott Williams and Wilkins. (Philadelphia, PA). 615–641. 2007.
6	Kidney Disease - Improving Global Outcomes Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Inter Suppl 2. 139–274. 2012.
7	Hellmark T, Niles JL, Collins AB, McCluskey RT and Brunmark C: Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol. 8:376–385. 1997.PubMed/NCBI
8	Fischer EG and Lager DJ: Anti-glomerular basement membrane glomerulonephritis: A morphologic study of 80 cases. Am J Clin Pathol. 125:445–450. 2006. View Article : Google Scholar : PubMed/NCBI
9	Hu SY, Jia XY, Yang XW, Yu F, Cui Z and Zhao MH: Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease. BMC Immunol. 14:422013. View Article : Google Scholar : PubMed/NCBI
10	Gao B, Li M, Xia W, Wen Y and Qu Z: Rapidly progressive glomerulonephritis due to anti-glomerular basement membrane disease accompanied by IgA nephropathy: A case report. Clin Nephrol. 81:138–141. 2014. View Article : Google Scholar : PubMed/NCBI
11	Wang A, Wang Y, Wang G, Zhou Z, Xun Z and Tan X: Mesangial IgA deposits indicate pathogenesis of anti-glomerular basement membrane disease. Mol Med Rep. 5:1212–1214. 2012.PubMed/NCBI
12	Carreras L, Poveda R, Bas J, Mestre M, Rama I and Carrera M: Goodpasture syndrome during the course of a Schönlein-Henoch purpura. Am J Kidney Dis. 39:E212002. View Article : Google Scholar : PubMed/NCBI
13	Kielstein JT, Helmchen U, Netzer KO, Weber M, Haller H and Floege J: Conversion of Goodpasture's syndrome into membranous glomerulonephritis. Nephrol Dial Transplant. 16:2082–2085. 2001. View Article : Google Scholar : PubMed/NCBI
14	Otten MA, Groeneveld TW, Flierman R, Rastaldi MP, Trouw LA, Faber-Krol MC, Visser A, Essers MC, Claassens J, Verbeek JS, et al: Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. J Immunol. 183:3980–3988. 2009. View Article : Google Scholar : PubMed/NCBI
15	Sheerin NS, Springall T, Carroll MC, Hartley B and Sacks SH: Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3-and C4-deficient mice. Clin Exp Immunol. 110:403–409. 1997. View Article : Google Scholar : PubMed/NCBI
16	Ma R, Cui Z, Liao YH and Zhao MH: Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease. J Clin Immunol. 33:172–178. 2013. View Article : Google Scholar : PubMed/NCBI
17	Takeda S, Takahashi M, Sado Y, Takeuchi K, Hakamata Y, Shimizu H, Kaneko T, Yamamoto H, Ito C, Ookawara S, et al: Prevention of glomerular crescent formation in glomerulonephritis by mycophenolate mofetil in rats. Nephrol Dial Transplant. 19:2228–2236. 2004. View Article : Google Scholar : PubMed/NCBI
18	Trpkov K, Abdulkareem F, Jim K and Solez K: Recurrence of anti-GBM antibody disease twelve years after transplantation associated with de novo IgA nephropathy. Clin Nephrol. 49:124–128. 1998.PubMed/NCBI
19	Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B and Vanrenterghem YF: Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 65:1842–1849. 2004. View Article : Google Scholar : PubMed/NCBI
20	Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A and Appel G: Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant. 20:2139–2145. 2005. View Article : Google Scholar : PubMed/NCBI
21	Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW and Lai KN: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 68:802–812. 2005. View Article : Google Scholar : PubMed/NCBI
22	Tang SC, Tang AW, Wong SS, Leung JC, Ho YW and Lai KN: Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 77:543–549. 2010. View Article : Google Scholar : PubMed/NCBI
23	Hogan J, Mohan P and Appel GB: Diagnostic tests and treatment options in glomerular disease: 2014 update. Am J Kidney Dis. 63:656–666. 2014. View Article : Google Scholar : PubMed/NCBI